Integrating traditional biomarkers and emerging predictors to assess neoadjuvant chemotherapy efficacy in breast cancer: a multifactorial analysis of Ki-67, CDK4, EGFR, TILs and ctDNA

Table 3 COX risk regression model

	B	SE	Wals	P value	OR	OR(95%CI)
TNM classification (II/III)	1.273	0.402	9.675	< 0.001	3.974	1.872 ~ 16.325
EGFR ( ±)	1.384	0.541	7.776	0.006	4.041	1.654 ~ 11.382
Ki-67 (low/high)	0.987	0.071	6.703	0.010	1.045	1.021 ~ 1.736

± : Positive relative to negative; II/III: The II phase relative to the III phase. Statistical analysis was performed using Cox proportional hazards regression model

ISSN: 1472-6874